{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:39:52Z","timestamp":1795127992244,"version":"4.10.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RO1AG061566"],"award-info":[{"award-number":["RO1AG061566"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P50AD16573"],"award-info":[{"award-number":["P50AD16573"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["PO01AG014449"],"award-info":[{"award-number":["PO01AG014449"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"publisher","award":["RB13-0192"],"award-info":[{"award-number":["RB13-0192"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gunvor och Josef Aners stiftelsen"},{"DOI":"10.13039\/100010771","name":"Loo och Hans Ostermans Stiftelse f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010823","name":"Tore Nilsons Stiftelse f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010823","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ki foundation for geriatrics diseases"},{"DOI":"10.13039\/100010773","name":"Demensf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-2019-04-3584"],"award-info":[{"award-number":["IP-2019-04-3584"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["Project 05817, 2017-0295, 2017-06086"],"award-info":[{"award-number":["Project 05817, 2017-0295, 2017-06086"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Tau pathology is a major age-related event in Down syndrome with Alzheimer\u2019s disease (DS-AD). Although recently, several different Tau PET tracers have been developed as biomarkers for AD, these tracers showed different binding properties in Alzheimer disease and other non-AD tauopathies. They have not been yet investigated in tissue obtained\n                      <jats:italic>postmortem<\/jats:italic>\n                      for DS-AD cases. Here, we evaluated the binding characteristics of two Tau PET tracers (\n                      <jats:sup>3<\/jats:sup>\n                      H-MK6240 and\n                      <jats:sup>3<\/jats:sup>\n                      H-THK5117) and one amyloid (\n                      <jats:sup>3<\/jats:sup>\n                      H-PIB) ligand in the medial frontal gyrus (MFG) and hippocampus (HIPP) in tissue from adults with DS-AD and DS cases with mild cognitive impairment (MCI) compared to sporadic AD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tau and amyloid autoradiography were performed on paraffin-embedded sections. To confirm respective ligand targets, adjacent sections were immunoreacted for phospho-Tau (AT8) and stained for amyloid staining using Amylo-Glo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The two Tau tracers showed a significant correlation with each other and with AT8, suggesting that both tracers were binding to Tau deposits.\n                      <jats:sup>3<\/jats:sup>\n                      H-MK6240 Tau binding correlated with AT8 immunostaining but to a lesser degree than the\n                      <jats:sup>3<\/jats:sup>\n                      H-THK5117 tracer, suggesting differences in binding sites between the two Tau tracers.\n                      <jats:sup>3<\/jats:sup>\n                      H-THK5117,\n                      <jats:sup>3<\/jats:sup>\n                      H-MK6240 and\n                      <jats:sup>3<\/jats:sup>\n                      H-PIB displayed dense laminar binding in the HIPP and MFG in adult DS brains. A regional difference in Tau binding between adult DS and AD was observed suggesting differential regional Tau deposition in adult DS compared to AD, with higher THK binding density in the MFG in adult with DS compared to AD. No significant correlation was found between\n                      <jats:sup>3<\/jats:sup>\n                      H-PIB and Amylo-Glo staining in adult DS brains suggesting that the amyloid PIB tracer binds to additional sites.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides new insights into the regional binding distribution of a first-generation and a second-generation Tau tracer in limbic and neocortical regions in adults with DS, as well as regional differences in Tau binding in adult with DS vs. those with AD. These findings provide new information about the binding properties of two Tau radiotracers for the detection of Tau pathology in adults with DS in vivo and provide valuable data regarding Tau vs. amyloid binding in adult DS compared to AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-020-00414-3","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T21:02:49Z","timestamp":1606078969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-7907","authenticated-orcid":false,"given":"L.","family":"Lemoine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ledreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Mufson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. E.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Simic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Doran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bharani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. D.","family":"Hamlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Granholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"414_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jalz.2014.10.007","volume":"11","author":"D Hartley","year":"2015","unstructured":"Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, et al. Down syndrome and Alzheimer's disease: common pathways, common goals. Alzheimers Dement. 2015;11:700\u20139.","journal-title":"Alzheimers Dement"},{"key":"414_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1006\/nbdi.2001.0431","volume":"8","author":"E Head","year":"2001","unstructured":"Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis. 2001;8:792\u2013806.","journal-title":"Neurobiol Dis"},{"key":"414_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1567205012666151020114607","volume":"13","author":"E Head","year":"2016","unstructured":"Head E, Lott IT, Wilcock DM, Lemere CA. Aging in Down syndrome and the development of Alzheimer's disease neuropathology. Curr Alzheimer Res. 2016;13:18\u201329.","journal-title":"Curr Alzheimer Res"},{"key":"414_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/gps.2321","volume":"25","author":"VP Prasher","year":"2010","unstructured":"Prasher VP, Sajith SG, Mehta P, Zigman WB, Schupf N. Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry. 2010;25:202\u20137.","journal-title":"Int J Geriatr Psychiatry"},{"key":"414_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/acn3.571","volume":"5","author":"NC Firth","year":"2018","unstructured":"Firth NC, Startin CM, Hithersay R, Hamburg S, Wijeratne PA, Mok KY, Hardy J, Alexander DC, LonDown SC, Strydom A. Aging related cognitive changes associated with Alzheimer's disease in Down syndrome. Ann Clin Transl Neurol. 2018;5:741\u201351.","journal-title":"Ann Clin Transl Neurol"},{"key":"414_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neurobiolaging.2017.05.019","volume":"58","author":"SL Hartley","year":"2017","unstructured":"Hartley SL, Handen BL, Devenny D, Mihaila I, Hardison R, Lao PJ, Klunk WE, Bulova P, Johnson SC, Christian BT. Cognitive decline and brain amyloid-beta accumulation across 3 years in adults with Down syndrome. Neurobiol Aging. 2017;58:68\u201376.","journal-title":"Neurobiol Aging"},{"key":"414_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JAD-170390","volume":"60","author":"MS Rafii","year":"2017","unstructured":"Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, et al. PET imaging of tau pathology and relationship to amyloid, longitudinal MRI, and cognitive change in Down syndrome: results from the Down syndrome biomarker initiative (DSBI). J Alzheimers Dis. 2017;60:439\u201350.","journal-title":"J Alzheimers Dis"},{"key":"414_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.nicl.2017.10.022","volume":"17","author":"N Neale","year":"2018","unstructured":"Neale N, Padilla C, Fonseca LM, Holland T, Zaman S. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome. Neuroimage Clin. 2018;17:263\u201371.","journal-title":"Neuroimage Clin"},{"key":"414_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40478-015-0220-4","volume":"3","author":"L Lemoine","year":"2015","unstructured":"Lemoine L, Saint-Aubert L, Marutle A, Antoni G, Eriksson JP, Ghetti B, Okamura N, Nennesmo I, Gillberg PG, Nordberg A. Visualization of regional tau deposits using (3) H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40.","journal-title":"Acta Neuropathol Commun"},{"key":"414_CR10","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/acschemneuro.8b00093","volume":"9","author":"NA Murugan","year":"2018","unstructured":"Murugan NA, Nordberg A, Agren H. Different positron emission tomography tau tracers bind to multiple binding sites on the tau fibril: insight from computational modeling. ACS Chem Neurosci. 2018;9:1757\u201367.","journal-title":"ACS Chem Neurosci"},{"key":"414_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"414_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13195-018-0401-z","volume":"10","author":"M Malek-Ahmadi","year":"2018","unstructured":"Malek-Ahmadi M, Chen K, Perez SE, He A, Mufson EJ. Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. Alzheimers Res Ther. 2018;10:90.","journal-title":"Alzheimers Res Ther"},{"key":"414_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-017-0325-z","volume":"9","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, Nag S, Tian H, Ghetti B, Okamura N, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017;9:96.","journal-title":"Alzheimers Res Ther"},{"key":"414_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"414_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.dadm.2018.01.007","volume":"10","author":"L Lemoine","year":"2018","unstructured":"Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Dement (Amst). 2018;10:232\u20136.","journal-title":"Alzheimers Dement (Amst)"},{"key":"414_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/0005-2736(83)90026-3","volume":"731","author":"B Pohl","year":"1983","unstructured":"Pohl B, Schmidt W. Comparative studies of purified and reconstituted monoamine oxidase from bovine liver mitochondria. Biochim Biophys Acta. 1983;731:338\u201345.","journal-title":"Biochim Biophys Acta"},{"key":"414_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jalz.2016.08.012","volume":"13","author":"ED Hamlett","year":"2017","unstructured":"Hamlett ED, Goetzl EJ, Ledreux A, Vasilevko V, Boger HA, LaRosa A, Clark D, Carroll SL, Carmona-Iragui M, Fortea J, et al. Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome. Alzheimers Dement. 2017;13:541\u20139.","journal-title":"Alzheimers Dement"},{"key":"414_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jnen\/62.9.917","volume":"62","author":"E Head","year":"2003","unstructured":"Head E, Lott IT, Hof PR, Bouras C, Su JH, Kim R, Haier R, Cotman CW. Parallel compensatory and pathological events associated with tau pathology in middle aged individuals with Down syndrome. J Neuropathol Exp Neurol. 2003;62:917\u201326.","journal-title":"J Neuropathol Exp Neurol"},{"key":"414_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/nan.12406","volume":"44","author":"I Milenkovic","year":"2018","unstructured":"Milenkovic I, Jarc J, Dassler E, Aronica E, Iyer A, Adle-Biassette H, Scharrer A, Reischer T, Hainfellner JA, Kovacs GG. The physiological phosphorylation of tau is critically changed in fetal brains of individuals with Down syndrome. Neuropathol Appl Neurobiol. 2018;44:314\u201327.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"414_CR20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nm0196-93","volume":"2","author":"JK Teller","year":"1996","unstructured":"Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med. 1996;2:93\u20135.","journal-title":"Nat Med"},{"key":"414_CR21","doi-asserted-by":"crossref","first-page":"10365","DOI":"10.1523\/JNEUROSCI.0630-07.2007","volume":"27","author":"MT Fodero-Tavoletti","year":"2007","unstructured":"Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365\u201371.","journal-title":"J Neurosci"},{"key":"414_CR22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jnc.13887","volume":"140","author":"G Yamin","year":"2017","unstructured":"Yamin G, Teplow DB. Pittsburgh compound-B (PiB) binds amyloid beta-protein protofibrils. J Neurochem. 2017;140:210\u20135.","journal-title":"J Neurochem"},{"key":"414_CR23","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1093\/brain\/awm191","volume":"130","author":"A Lockhart","year":"2007","unstructured":"Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130:2607\u201315.","journal-title":"Brain"},{"key":"414_CR24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-180071","volume":"64","author":"V Leinonen","year":"2018","unstructured":"Leinonen V, Rauramaa T, Johansson J, Bottelbergs A, Tesseur I, van der Ark P, Pemberton D, Koivisto AM, Jaaskelainen JE, Hiltunen M, et al. S-[18F]THK-5117-PET and [11C]PIB-PET imaging in idiopathic Normal pressure hydrocephalus in relation to confirmed amyloid-beta plaques and tau in brain biopsies. J Alzheimers Dis. 2018;64:171\u20139.","journal-title":"J Alzheimers Dis"},{"key":"414_CR25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jneumeth.2012.05.019","volume":"209","author":"L Schmued","year":"2012","unstructured":"Schmued L, Raymick J, Tolleson W, Sarkar S, Zhang YH, Bell-Cohn A. Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer especially suited for multiple labeling and large scale quantification studies. J Neurosci Methods. 2012;209:120\u20136.","journal-title":"J Neurosci Methods"},{"key":"414_CR26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, Pankratz VS, Senjem ML, Gunter JL, Mielke MM, et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013;80:890\u20136.","journal-title":"Neurology"},{"key":"414_CR27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neurobiolaging.2017.03.005","volume":"54","author":"H LeVine 3rd","year":"2017","unstructured":"LeVine H 3rd, Spielmann HP, Matveev S, Cauvi FM, Murphy MP, Beckett TL, McCarty K, Lott IT, Doran E, Schmitt F, Head E. Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan. Neurobiol Aging. 2017;54:163\u20139.","journal-title":"Neurobiol Aging"},{"key":"414_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000442941","volume":"41","author":"LM Fonseca","year":"2016","unstructured":"Fonseca LM, Yokomizo JE, Bottino CM, Fuentes D. Frontal lobe degeneration in adults with Down syndrome and Alzheimer's disease: a review. Dement Geriatr Cogn Disord. 2016;41:123\u201336.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"414_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2788.2010.01271.x","volume":"54","author":"D Adams","year":"2010","unstructured":"Adams D, Oliver C. The relationship between acquired impairments of executive function and behaviour change in adults with Down syndrome. J Intellect Disabil Res. 2010;54:393\u2013405.","journal-title":"J Intellect Disabil Res"},{"key":"414_CR30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112\u201334.","journal-title":"Mol Psychiatry"},{"key":"414_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, Stone CK, Rowley HA, Johnson SC, Christian BT. In vivo characterization and quantification of neurofibrillary tau PET Radioligand (18) F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60:93\u20139.","journal-title":"J Nucl Med"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-020-00414-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13024-020-00414-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-020-00414-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T21:04:42Z","timestamp":1606079082000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-020-00414-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1186\/s13024-020-00414-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-48040\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-48040\/v2","asserted-by":"object"}]},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"10 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was completed under each University\u2019s Institutional Review Board (IRB) with either the determination of Not Human Research (NHR) Criteria set forth by the Code of Federal Regulations (45CFR46) or as Human Subjects Research with the requirement for written informed consent from the participants or the participants Legally Authorized Representative per local statute (UCI-ADRC).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors do not report any conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}